专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10654892B2 Method for activating helper T cell 有权
公开(公告)号：US10654892B2
公开(公告)日：2020-05-19
申请号：US13877768
申请日：2011-10-04
申请人： Haruo Sugiyama , Shinji Sogo , Masayoshi Sato , Ryuki Kitamoto , Yoshihiro Goto
发明人： Haruo Sugiyama , Shinji Sogo , Masayoshi Sato , Ryuki Kitamoto , Yoshihiro Goto
IPC分类号： A61K39/00 , C12N5/0783 , C07K7/08 , C07K14/82 , A61K35/17
摘要： The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1*0101 molecule, an HLA-DRB1*0401 molecule, an HLA-DRB1*0403 molecule, an HLA-DRB1*0406 molecule, an HLA-DRB1*0803 molecule, an HLA-DRB1*0901 molecule, an HLA-DRB1*1101 molecule, an HLA-DRB3*0202 molecule, an HLA-DRB4*0101 molecule, an HLA-DPB1*0201 molecule or an HLA-DPB1*0301 molecule, and the like.

2. 发明授权

US09266932B2 Cancer antigen helper peptide 有权
标题翻译：癌抗原辅助肽
公开(公告)号：US09266932B2
公开(公告)日：2016-02-23
申请号：US13265805
申请日：2010-04-22
申请人： Haruo Sugiyama
发明人： Haruo Sugiyama
IPC分类号： A61K39/00 , C07K14/47 , G01N33/574 , A61K38/00
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/55566 , C07K14/4702 , C07K16/18 , C07K16/30 , C12N5/0634 , G01N33/56966 , G01N33/57438
摘要： The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like.
摘要翻译：本发明涉及具有由WT1蛋白衍生的连续氨基酸组成的氨基酸序列的WT1肽，通过结合MHC II类分子诱导WT1特异性辅助T细胞，包含它们的药物组合物等。

3. 发明授权

US09097717B2 Methods of killing myeloma stem and precursor cells by administering anti-CD48 antibodies 有权
标题翻译：通过施用抗CD48抗体杀死骨髓瘤干和前体细胞的方法
公开(公告)号：US09097717B2
公开(公告)日：2015-08-04
申请号：US13263206
申请日：2010-04-09
申请人： Naoki Hosen , Haruo Sugiyama
发明人： Naoki Hosen , Haruo Sugiyama
IPC分类号： A61K39/395 , G01N33/574 , C07K16/28 , G01N33/50 , A61K39/00
CPC分类号： G01N33/57492 , A61K2039/505 , C07K16/2803 , C07K2317/73 , C07K2317/734 , G01N33/5011 , G01N2333/70503 , G01N2500/04
摘要： The present invention provides a therapeutic agent, for diseases in which neoplastic proliferation of plasma cells occurs, which is characterized by containing an anti-human CD48 monoclonal antibody and having cellular cytotoxicity to cells expressing human CD48; and the monoclonal antibody. In addition, the present invention provides a method for screening an active ingredient of a therapeutic agent for diseases in which neoplastic proliferation of plasma cells occurs, the method including the following processes: (1) a process of sorting a substance that binds specifically to human CD48; and (2) a process of sorting a substance having cellular cytotoxicity.
摘要翻译：本发明提供了治疗剂，用于发生血浆细胞的肿瘤增生的疾病，其特征在于含有抗人CD48单克隆抗体并且对表达人CD48的细胞具有细胞毒性; 和单克隆抗体。此外，本发明提供了筛选发生血浆细胞肿瘤增生的疾病的治疗剂的活性成分的方法，所述方法包括以下方法：（1）对与人特异性结合的物质进行分选的方法 CD48; 和（2）分选具有细胞毒性的物质的方法。

4. 发明授权

US08759483B2 HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the same 有权
标题翻译： HLA-A * 3303限制性WT1肽和包含其的药物组合物
公开(公告)号：US08759483B2
公开(公告)日：2014-06-24
申请号：US12280268
申请日：2007-02-21
申请人： Haruo Sugiyama
发明人： Haruo Sugiyama
IPC分类号： A61K39/00 , C07K7/06
CPC分类号： A61K38/08 , A61K38/00 , A61K39/00 , C07K7/06 , C07K14/4748 , G01N33/505 , G01N33/574
摘要： Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method for the induction of a WT1-specific CTL using the peptide.
摘要翻译：公开的是包含由WT1蛋白衍生的连续9个氨基酸残基组成的氨基酸序列的肽，其中氨基酸序列中第2位的氨基酸残基选自Ala，Ile，Leu，Val ，Phe，Tyr，Ser和Asp，氨基酸序列中第9位的氨基酸残基为Arg; 编码该肽的多核苷酸; 包含该肽的药物组合物; 以及使用该肽诱导WT1特异性CTL的方法。

5. 发明授权

US08735357B2 Method of inducing antigen-specific T cells 有权
标题翻译：诱导抗原特异性T细胞的方法
公开(公告)号：US08735357B2
公开(公告)日：2014-05-27
申请号：US10490873
申请日：2002-09-27
申请人： Haruo Sugiyama
发明人： Haruo Sugiyama
IPC分类号： A61K38/00
CPC分类号： A61K39/00 , A61K39/0011 , A61K2039/545 , A61K2039/55522 , A61K2039/55583 , A61K2039/55594 , C12N5/0636
摘要： The present invention provides a method for inducing antigen-specific T cells in a patient comprising administering to said patient in need thereof composition (a) which comprises an antigen protein or an antigen peptide as an active ingredient and composition (b) which comprises a non-specific immunopotentiator as an active ingredient, wherein composition (b) is administered in advance and then composition (a) is administered, as well as related pharmaceutical compositions.
摘要翻译：本发明提供一种用于诱导患者中抗原特异性T细胞的方法，其包括向所述需要的患者施用包含抗原蛋白或抗原肽作为活性成分的组合物（a）和包含非抗原蛋白的组合物（b）特异性免疫增强剂作为活性成分，其中组合物（b）预先施用，然后施用组合物（a），以及相关的药物组合物。

6. 发明申请

US20120045465A1 CANCER ANTIGEN HELPER PEPTIDE 有权
标题翻译：癌症抗原肽
公开(公告)号：US20120045465A1
公开(公告)日：2012-02-23
申请号：US13265805
申请日：2010-04-22
申请人： Haruo Sugiyama
发明人： Haruo Sugiyama
IPC分类号： A61K39/00 , C07H21/04 , C12N15/63 , C12Q1/06 , A61K31/7088 , A61P35/00 , C12N5/071 , C12Q1/04 , C07K7/08 , C07K16/18
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/55566 , C07K14/4702 , C07K16/18 , C07K16/30 , C12N5/0634 , G01N33/56966 , G01N33/57438
摘要： The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like.
摘要翻译：本发明涉及具有由WT1蛋白衍生的连续氨基酸组成的氨基酸序列的WT1肽，通过结合MHC II类分子诱导WT1特异性辅助T细胞，包含它们的药物组合物等。

7. 发明申请

US20120021994A1 NOVEL CANCER ANTIGEN EEF2 审中-公开
标题翻译：新型癌症抗原EEF2
公开(公告)号：US20120021994A1
公开(公告)日：2012-01-26
申请号：US13143492
申请日：2010-01-08
申请人： Haruo Sugiyama , Yusuke Oji
发明人： Haruo Sugiyama , Yusuke Oji
IPC分类号： A61K38/08 , C12N15/11 , C12N15/85 , A61P35/00 , C12Q1/68 , A61K31/713 , C07K7/06 , C07H21/02 , G01N33/566
CPC分类号： A61K39/0011 , A61K31/713 , A61K38/00 , A61K38/08 , C07K14/47 , C07K14/82 , C12N15/113 , C12N15/1135 , C12N2310/11 , C12N2310/14 , C12N2310/531 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G01N33/57484
摘要： The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject.
摘要翻译：本发明提供使用各种癌症中表达的蛋白质检测癌症的方法，以及使用该蛋白质作为指标来治疗或预防这种癌症的药物组合物。此外，本发明提供含有源自蛋白质的癌抗原肽的药物组合物。更具体地，该方法包括确定从受试者获得的样品中eEF2多肽或eEF2抗体的存在或量的步骤。

8. 发明申请

US20100292160A1 HLA-A* 3303-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 有权
标题翻译： HLA-A * 3303-限制性WT1肽和包含其的药物组合物
公开(公告)号：US20100292160A1
公开(公告)日：2010-11-18
申请号：US12280268
申请日：2007-02-21
申请人： Haruo Sugiyama
发明人： Haruo Sugiyama
IPC分类号： A61K38/08 , C07K7/06 , C07H21/00 , A61K31/713 , A61P35/00 , C12N15/63 , C12N5/00 , C12N5/02 , C12Q1/02
CPC分类号： A61K38/08 , A61K38/00 , A61K39/00 , C07K7/06 , C07K14/4748 , G01N33/505 , G01N33/574
摘要： Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and others.
摘要翻译：公开的是包含由WT1蛋白衍生的连续9个氨基酸残基组成的氨基酸序列的肽，其中氨基酸序列中第2位的氨基酸残基选自Ala，Ile，Leu，Val ，Phe，Tyr，Ser和Asp，氨基酸序列中第9位的氨基酸残基为Arg; 编码该肽的多核苷酸; 包含该肽的药物组合物; 和别的。

9. 发明授权

US07807792B2 Tumor antigen based on products of the tumor suppressor gene WT1 有权
标题翻译：基于肿瘤抑制基因WT1产物的肿瘤抗原
公开(公告)号：US07807792B2
公开(公告)日：2010-10-05
申请号：US12366200
申请日：2009-02-05
申请人： Haruo Sugiyama , Yoshihiro Oka
发明人： Haruo Sugiyama , Yoshihiro Oka
IPC分类号： C07K16/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , C07K14/4703 , C07K14/82
摘要： A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.
摘要翻译：肿瘤抗原包含Wilms肿瘤抑制基因WT1的产物或由含有锚定氨基酸的7-30个连续氨基酸组成的肽，作为活性成分，用于结合所述的主要组织相容性复合体（MHC）I类氨基酸序列和包含所述抗原的疫苗。

10. 发明授权

US07342092B2 Cancer antigen peptide formulations 有权
标题翻译：癌抗原肽制剂
公开(公告)号：US07342092B2
公开(公告)日：2008-03-11
申请号：US10527692
申请日：2003-09-12
申请人： Haruo Sugiyama
发明人： Haruo Sugiyama
IPC分类号： A61K38/00 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00
CPC分类号： C07K14/82 , A61K9/107
摘要： Cancer antigen peptides derived from WT1 which have an in vivo efficacy, particularly a clinical usefulness, and cancer vaccines as dosage forms suitable for said cancer antigen peptides, are provided.The invention relates to water-in-oil emulsions which comprise as an effective ingredient either one or both of peptides selected from the group consisting of a peptide having an amino acid sequence of Cys Met Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 2), and a peptide having an amino acid sequence of Cys Tyr Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 3), as well as processes for preparation of said emulsion.
摘要翻译：提供了具有体内功效，特别是临床用途的源自WT1的癌抗原肽和作为适合所述癌抗原肽的剂型的癌疫苗。本发明涉及油包水乳液，其包含作为有效成分的一种或两种肽，所述肽选自具有氨基酸序列Cys Met Thr Trp Asn Gln Met Asn Leu（SEQ ID NO： 2）和具有Cys Tyr Thr Trp Asn Gln Met Asn Leu（SEQ ID NO：3）的氨基酸序列的肽，以及所述乳液的制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式